Report #2836164

Overview

Sex

Unknown

Age

Age unknown

State

MI

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

subcutaneous product administered by other route; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in an specified number of patients who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular) .5 ml. On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: subcutaneous product administered by other route). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-APR-2025 The reporter stated that 12 patients were given a dose of Priorix intramuscularly instead of subcutaneously. HCP was asked for initials, gender, DOB, lot number, location of IM injection, and date of administration for all 12 patients. The reporter did not want to give the information at the time of the call. The patients received Priorix intramuscularly instead of subcutaneously, which led to subcutaneous injection formulation administered by other route.